Possible side effects of bosutinib/bosutinib

Bosutinib/Bosutinib is a targeted therapy drug for chronic myelogenous leukemia (CML). It mainly prevents the proliferation of cancer cells by inhibiting the activity of BCR-ABL tyrosine kinase. Although bosutinib has demonstrated significant efficacy in clinical application, it is still associated with certain adverse reactions, and these reactions may vary significantly among different patient groups.

According to clinical research results, for patients with newly diagnosed chronic Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+CML) who are resistant or intolerant to previous treatments, the most common adverse reactions include diarrhea, rash, nausea, abdominal pain, vomiting and fatigue. These symptoms are usually noticeable early in treatment and may lessen as treatment progresses. However, diarrhea is often considered the most bothersome side effect by patients. In severe cases, it may lead to dehydration and electrolyte imbalance, so patients need to be closely monitored and timely intervention measures need to be taken.

In addition, liver function impairment is also a side effect that needs to be paid attention to during the use of bosutinib. While receiving this drug, patients need to undergo regular liver function tests to ensure that the liver is not excessively damaged. Complications such as respiratory infections, fever, and headaches are also common and may be related to changes in the patient's immune system or the direct effects of the medication.

In children, the adverse effects of bosutinib are similar to those seen in adults, particularly diarrhea and abdominal pain. These symptoms may significantly affect a child's quality of life, so clinicians need to take appropriate measures to mitigate the impact of these adverse effects.

In addition to the common adverse reactions mentioned above, some rare but serious side effects have been reported after bosutinib was marketed, such as thrombotic microangiopathy and Stevens-Johnson syndrome. These serious side effects require physicians to carefully assess patient risks when using bosutinib and respond quickly if symptoms occur. Overall, a deeper understanding of bosutinib's side effects will help improve patient safety and treatment effectiveness.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3